BioMedNewsBreaks - Soligenix Inc.'s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soligenix Inc.

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte(TM) in Ongoing Clinical Trials
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.
Positive Outcome in 75% of CTCL Patients Treated with HyBryte(TM) for 18 Weeks
IBN Initiates Coverage of Soligenix Inc.
Soligenix Announces Publication Demonstrating CiVax(TM) Booster Induces Rapid Broad Protection Against COVID-19 Variants
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
HyBryte(TM) Treatment Studies Presented at Two Medical Conferences in March

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.